Phaseline

Targets › MRPL11

MRPL11 (Large ribosomal subunit protein uL11m): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on MRPL11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nanfang Hospital, Southern Medical UniversityHomoharringtonine (HHT)
Protein synthesis inhibitor
MRPL11Phase 3Newly Diagnosed Acute Myeloid Leukemia With High RiskDec 2026

Conditions

Newly Diagnosed Acute Myeloid Leukemia With High Risk (1)

Modalities

small molecule (1)

Companies

Nanfang Hospital, Southern Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.